Prostaglandin E1 treatment in patients with end-stage chronic renal failure Clinical.doc

Prostaglandin E1 treatment in patients with end-stage chronic renal failure Clinical.doc

  1. 1、本文档共11页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Prostaglandin E1 treatment in patients with end-stage chronic renal failure Clinical

 PAGE \* MERGEFORMAT 11 Prostaglandin E1 treatment in patients with end-stage chronic renal failure Clinical Of: Ji-ren Zhang Zhong Jing-Hua Wang Yong Xiang Wu Rui-Lin Liu Yuan Shenping [Abstract] Objective To evaluate the application of prostaglandin E1 (PGE1) treatment of end-stage chronic renal failure (ESRF) of clinical efficacy. Methods 22 patients with end-stage chronic renal failure (ESRF) in elderly patients into two groups, the control group 10 cases, according to Conventional disease medication to control blood pressure, correction of anemia, acidosis, electrolyte disorders. experimental group of 12 patients without the use of group based on the use PGE1 200 g in 10% glucose solution 500 ml intravenously, 1 / d, 3 courses of treatment were followed up for 3 months were observed in the clinical symptoms, laboratory tests, mortality and other related indicators. Results The edema, backache, fatigue, urine output, loss of appetite, skin itching and other symptoms than the control group improvement obvious. experimental urea nitrogen (BUN), creatinine (Scr), endogenous creatinine clearance rate (Ccr), urinary protein control group, the difference was significant (P lt;0.05). 25% mortality in the experimental group, 50% of the control group mortality difference between two groups were significantly (P lt;0.05). Conclusions PGE1 can slow down the process of chronic renal insufficiency, improving renal function and reduce mortality in end-stage chronic renal failure and improve prognosis. [Keywords:] prostaglandin E1; end stage chronic renal failure [Abstract] ObjectiveTo investigate the effect of prostaglandin-E1 (PGE1) on the treatment for end-stage renal failure (ESRF). Methods22 patients with ESRFwere chosen and divided into groups with and without PGE1 treatment. Patientsinboth groups were given basic treatment. PGE1 was added into group with PGE1 treatment. Patients of both groups were followed up for 3 months. Blood urea nitrogen (BUN), se

文档评论(0)

hhuiws1482 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

版权声明书
用户编号:5024214302000003

1亿VIP精品文档

相关文档